2-methyl-9-phenyl-2,3,4,9-tetrahydro-1H-indeno[2,1-c]pyridin-2-ium;2,3,4-trihydroxy-4-oxobutanoate

• 分子结构分类: 有机化合物 - 苯类化合物 - 茚和异茚
• 英文名称: 2-methyl-9-phenyl-2,3,4,9-tetrahydro-1H-indeno[2,1-c]pyridin-2-ium;2,3,4-trihydroxy-4-oxobutanoate
• 化学式: C23H25NO6
• 分子量: 411.4
• InChiKey: WFXURHIXPXVPGM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  30
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  118
• 氢给体数：
  4
• 氢受体数：
  7

文献信息

• Polymeric depots for localization of agent to biological sites
  申请人：TRUSTEES OF BOSTON UNIVERSITY

  公开号：US10251841B2

  公开（公告）日：2019-04-09

  Provided herein are polymeric particles and compounds and processes that can be used to prepare polymer-based particles and methods of using those particles to localize or concentrate a subsequently delivered agent to an in vivo site.

  本文提供了可以用于制备基于聚合物的颗粒的聚合物颗粒、化合物和过程，以及利用这些颗粒将随后传递的药剂定位或浓缩到体内部位的方法。
• Films and Particles
  申请人：Colson Yolonda

  公开号：US20080075718A1

  公开（公告）日：2008-03-27

  Described herein are compounds and processes that can be used to prepare polymer-based films, particles, gels and related compositions, and processes for delivery of agents, and other uses.

  本文描述了可用于制备基于聚合物的薄膜、颗粒、凝胶及相关组合物的化合物和工艺，以及用于传递药剂和其他用途的工艺。
• [EN] HYDRAZONE COMPOUNDS AND THEIR USE<br/>[FR] COMPOSÉS D'HYDRAZONE ET LEUR UTILISATION
  申请人：STEIN PHILIP

  公开号：WO2010132615A1

  公开（公告）日：2010-11-18

  The present invention relates to hydrazone compounds of Formula I: (I) and pharmaceutically acceptable salts and stereoisomers thereof, wherein R1, R2, R3, R4, L1, and L2 are defined as set forth in the specification. The invention is also directed to the use of compounds of Formula I as inhibitors of TRPM5 protein.

  本发明涉及式I的腙化合物：(I)及其药用可接受的盐和立体异构体，其中R1、R2、R3、R4、L1和L2的定义如规范中所述。该发明还涉及将式I的化合物用作TRPM5蛋白的抑制剂。
• Phosphate based biodegradable polymers
  申请人：——

  公开号：US20020155092A1

  公开（公告）日：2002-10-24

  Featured are biodegradable polymers comprising repeat units derived from cyclic phosphate monomers and optionally further comprising repeat units derived from lactide or caprolactone monomers. Also featured are methods for preparing the biodegradable polymers of the invention and biodegradable polymer compositions comprising a biologically active substance and a biodegradable polymer. Additionally featured are articles and microspheres prepared from biodegradable polymers and polymer compositions of the invention. Further, methods for the controlled release of a biologically active substance using the biodegradable polymers of the invention are also described.

  特色是由环磷酸酯单体衍生的重复单元构成的可生物降解聚合物，可选地还包括由乳酸或己内酯单体衍生的重复单元。还有涉及制备该发明的可生物降解聚合物的方法，以及包括生物活性物质和可生物降解聚合物的可生物降解聚合物组合物。此外，还有由可生物降解聚合物和该发明的聚合物组合物制备的物品和微球。另外，还描述了使用该发明的可生物降解聚合物进行生物活性物质的控制释放的方法。
• Dendrimers as molecular translocators
  申请人：Goodman Murray

  公开号：US20060216265A1

  公开（公告）日：2006-09-28

  Transport molecules include a dendrimer and a biologically active molecule. The dendrimer of such transport molecules includes at least one guanidine group, at least one protonated guanidine group, at least one protected guanidine group, at least one amidine group, at least one protonated amidine group, at least one protected amidine group, at least one ureido group, at least one protonated ureido group, at least one protected ureido group, at least one thioureido group, at least one protonated thioureido group, or at least one protected thioureido group. The biologically active molecule is bonded to the dendrimer. A method of increasing the bioavailability of a drug includes bonding the drug to a dendrimer of the invention.

  转运分子包括一种树枝状聚合物和一种生物活性分子。这些转运分子的树枝状聚合物包括至少一个胍基团、至少一个质子化的胍基团、至少一个保护的胍基团、至少一个酰胺基团、至少一个质子化的酰胺基团、至少一个保护的酰胺基团、至少一个脲基团、至少一个质子化的脲基团、至少一个保护的脲基团、至少一个硫脲基团、至少一个质子化的硫脲基团，或至少一个保护的硫脲基团。生物活性分子与树枝状聚合物结合。一种增加药物生物利用度的方法包括将药物与本发明的树枝状聚合物结合。